National Bank of Canada
RIGL icon

National Bank of Canada’s Rigel Pharmaceuticals RIGL Stock Holding History

National Bank of Canada’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
5,212
+515
+11% +$17.3K ﹤0.01% 1708
2025
Q4 		$201K Buy
4,697
+879
+23% +$33.1K ﹤0.01% 1594
2025
Q3 		$108K Buy
+3,818
New +$114K ﹤0.01% 1733
2024
Q4 		– Sell
-400
Closed -$6.47K – 3166
2024
Q3 		$6.47K Hold
400
– – ﹤0.01% 2163
2024
Q2 		$3.36K Hold
400
– – ﹤0.01% 2347
2024
Q1 		$3.94K Hold
400
– – ﹤0.01% 2354
2023
Q4 		$5.8K Hold
400
– – ﹤0.01% 2270
2023
Q3 		$4.12K Sell
400
-100
-20% -$1.2K ﹤0.01% 2389
2023
Q2 		$6.4K Buy
500
+100
+25% +$1.35K ﹤0.01% 2286
2023
Q1 		$5.28K Hold
400
– – ﹤0.01% 2278
2022
Q4 		$6K Hold
400
– – ﹤0.01% 2289
2022
Q3 		$5K Hold
400
– – ﹤0.01% 2348
2022
Q2 		$5K Hold
400
– – ﹤0.01% 2436
2022
Q1 		$12K Hold
400
– – ﹤0.01% 2324
2021
Q4 		$11K Buy
+400
New +$12.1K ﹤0.01% 2331

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's RIGL Position: Q1 2026 in Review

National Bank of Canada increased its Rigel Pharmaceuticals (RIGL) stake by 11% in Q1 2026, buying an estimated $17.3K and bringing the position to 5,212 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

National Bank of Canada first reported a position in RIGL in Q4 2021 and has held it in 15 quarters since. The position peaked at $201K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • National Bank of Canada held 5,212 shares of Rigel Pharmaceuticals worth $141K as of Q1 2026.
  • National Bank of Canada bought 515 Rigel Pharmaceuticals shares in Q1 2026, an estimated $17.3K.
  • Rigel Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1708 holding.
  • National Bank of Canada first reported a position in Rigel Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • National Bank of Canada's Rigel Pharmaceuticals position peaked at $201K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.